Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 47.9% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,295,837 shares of the company's stock after acquiring an additional 419,600 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 1.04% of Vaxcyte worth $148,075,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of PCVX. RA Capital Management L.P. grew its holdings in shares of Vaxcyte by 4.0% in the first quarter. RA Capital Management L.P. now owns 8,203,754 shares of the company's stock worth $560,398,000 after purchasing an additional 312,500 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Vaxcyte by 18.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company's stock worth $216,966,000 after buying an additional 498,359 shares in the last quarter. Driehaus Capital Management LLC raised its holdings in shares of Vaxcyte by 3.6% in the second quarter. Driehaus Capital Management LLC now owns 1,934,747 shares of the company's stock valued at $146,093,000 after acquiring an additional 66,940 shares in the last quarter. Novo Holdings A S grew its holdings in Vaxcyte by 12.4% during the 2nd quarter. Novo Holdings A S now owns 950,000 shares of the company's stock worth $71,734,000 after acquiring an additional 105,000 shares in the last quarter. Finally, Maverick Capital Ltd. raised its position in shares of Vaxcyte by 93.7% in the 2nd quarter. Maverick Capital Ltd. now owns 687,908 shares of the company's stock worth $51,944,000 after acquiring an additional 332,777 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Bank of America boosted their price objective on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a "buy" rating in a research note on Wednesday, September 4th. Jefferies Financial Group increased their price target on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a "buy" rating in a report on Tuesday, September 3rd. Leerink Partners lifted their price objective on shares of Vaxcyte from $106.00 to $153.00 and gave the company an "outperform" rating in a research note on Tuesday, September 3rd. Mizuho boosted their target price on shares of Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a research report on Tuesday, September 10th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Vaxcyte in a research report on Wednesday, November 6th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vaxcyte has a consensus rating of "Buy" and an average target price of $147.50.

Vaxcyte Stock Performance

Vaxcyte stock traded up $3.16 during mid-day trading on Monday, hitting $91.70. The company had a trading volume of 1,750,097 shares, compared to its average volume of 903,407. The business has a fifty day moving average of $107.89 and a 200 day moving average of $89.57. Vaxcyte, Inc. has a 1 year low of $48.35 and a 1 year high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same quarter last year, the company posted ($0.91) EPS. Research analysts forecast that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Grant Pickering sold 2,366 shares of the firm's stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $103.89, for a total transaction of $245,803.74. Following the sale, the chief executive officer now owns 137,398 shares in the company, valued at $14,274,278.22. This trade represents a 1.69 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total transaction of $927,520.00. Following the transaction, the chief financial officer now owns 90,383 shares in the company, valued at approximately $10,479,005.02. The trade was a 8.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 102,464 shares of company stock worth $11,455,576. 3.10% of the stock is owned by corporate insiders.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.